A N Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.85 M
as on 16-11-2024
- Company Age 24 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.97 Cr
as on 16-11-2024
- Satisfied Charges ₹ 5.15 Cr
as on 16-11-2024
- Revenue 13.79%
(FY 2023)
- Profit 19.77%
(FY 2023)
- Ebitda 21.20%
(FY 2023)
- Net Worth 11.64%
(FY 2023)
- Total Assets 14.51%
(FY 2023)
About A N Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.85 M.
The company currently has active open charges totaling ₹7.97 Cr. The company has closed loans amounting to ₹5.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anil Arora and Rishabh Arora serve as directors at the Company.
- CIN/LLPIN
U24233DL2000PTC108617
- Company No.
108617
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Nov 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at A N Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Arora  | Managing Director | 22-Nov-2000 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rishabh Arora | Director | 03-Jan-2023 | Current |
Financial Performance of A N Pharmaceuticals.
A N Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.79% increase. The company also saw a substantial improvement in profitability, with a 19.77% increase in profit. The company's net worth Soared by an impressive increase of 11.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of A N Pharmaceuticals?
In 2023, A N Pharmaceuticals had a promoter holding of 92.26% and a public holding of 7.74%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aurora Nutraceuticals Private LimitedActive 21 years 7 monthsAnil Arora and Rishabh Arora are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 03 May 2021 | ₹6.66 M | Open |
Hdfc Bank Limited Creation Date: 04 Jan 2021 | ₹7.30 Cr | Open |
Ing Vysya Bank Limited Creation Date: 09 Feb 2011 | ₹3.00 Cr | Satisfied |
How Many Employees Work at A N Pharmaceuticals?
Unlock and access historical data on people associated with A N Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of A N Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped A N Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
